Alltracel announces the successful development of Phytopeutics(TM), a patented
range of dermal health solutions for the functional cosmetic/cosmeceuticals
market
- - Derived from Alltracel's proven wound healing technology following
successful completion of 12 month cosmetic testing program - -
-- Features proven multi function dermal health capability including collagen
promotion, anti-ageing, antioxidation, skin hydration and skin repair -
7.00am May 3rd, 2007: Dublin, Ireland & Prague, Czech Republic
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the
Healthcare Innovation Group focused on the Wound Care, Oral Care and
Cardiovascular Health markets, is today pleased to confirm the successful
development of Phytopeutics(TM), a range of dermal health solutions derived from
Alltracel's patented technology targeting the functional cosmetic/cosmeceuticals
market.
Alltracel has been working on the Phytopeutics(TM) range of dermal health
solutions during the last year utilising internal and independent testing
capabilities to generate a number of skin health compounds from its patented
technologies. The work was a direct result of findings from Alltracel's
successful healing and anti-microbial trials last year. A subsequent specific
study of the mechanisms involved revealed additional beneficial skin properties
previously unexplored. Further development and trialing has produced a range of
compounds that can be utilised for many cosmeceutical applications including
collagen promotion, anti-ageing, antioxidation, hydration and skin repair.
Specific technology benefits:
Collagen Promotion - Phytopeutics(TM) compounds were found to dramatically
increase the quantity of collagen produced by skin cells, replenishing the skins
natural strength and elasticity to combat the signs of ageing. Efficacy results
significantly exceeded current commercially available collagen promotion
technologies.
Antioxidation - A Phytopeutics(TM) antioxidant compound performed excellently
when compared to current industry antioxidants. An antioxidant can neutralize
skin damaging free radicals generated by sun exposure, environmental toxins,
poor diet etc... .
Hydration - Phytopeutics(TM) compounds can bind many times their own weight in
water and are well suited for use as topical moisturisers. Incorporation of the
technology helps retain the skins' moisture and helps reduce the signs of skin
damage and ageing.
Antimicrobial - Many of the Phytopeutics(TM) compounds have been demonstrated to
be antimicrobial activity. These may be employed as antimicrobials in products
to treat conditions such as dandruff, body odour and acne.
Further technological background is available at www.phytopeutics.com.
Alltracel Pharmaceutical's CEO, Tony Richardson, commented:
"The successful development of the Phytopeutics(TM) range of patented skin
health solutions represents an exciting opportunity for the company to enter the
high consumption, high margin international cosmeceuticals marketplace. The
technology provides a full range of dermal health solutions for all ages of
skin.
"Last year's proven healing and anti-microbial findings on our woundcare
technologies were the inspiration for investigating and testing the skin
repairing capability on variations of our patented technologies. The successful
completion of these trials has resulted in the development of the
Phytopeutics(TM) technology brand."
Ends
For Further Information Contact:
Dublin: Denise Cronin Alltracel: +353 1 235 2162
press@alltracel.com
London: Deborah Scott Financial Dynamics: +44 207 831 3113
New York: Sean Leous Financial Dynamics: +1 212 850 5626
Notes to Editors:
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.
Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovation technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (www.westoneproducts.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of Nanospider(TM) technology for the global
healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals plc.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics
s.r.o.
This information is provided by RNS
The company news service from the London Stock Exchange
Alltracel Pharmaceuticals PLC announces Research Update
| Source: Alltracel Pharmaceuticals Plc
Dublin -- (MARKET WIRE) -- May 3, 2007 --